NEWS
Shortened Exclusivity Could Save $31B
“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.”
MGA’s Alex Brill on CNBC’s Squawk Box
Today, Brill discusses President Trump’s potential appointment options for the Federal Reserve Board of Governors.
Biologics are Not Natural Monopolies
Recently, several physicians and health policy analysts took to the Health Affairs blog to propose what was, to anyone who has been following biosimilars for the last decade or more, a surprising and concerning idea: that biosimilars should be abandoned.
2018 Charitable Giving Dips, as Predicted
A Giving USA report released last week shows that US households’ charitable donations in 2018 experienced the largest decline since the Great Recession. We hate to say we told you so, but we told you so.
MGA’s Alex Brill on CNBC’s Squawk Box
Watch Brill’s latest news clip from his CNBC interview where he discusses raising tax rates on the rich.
If Trump Country Soars, Will the President Glide to a Second Term?
“He (Alex Brill) found that 10 states — many of them with large rural populations — broke records in 2019 by hitting their lowest unemployment rates in history: Alabama, Iowa, Kentucky, Mississippi, North Dakota, Pennsylvania, South Carolina, Tennessee, Vermont and Wisconsin.”
MGA’s Paper on State Opioid Taxes is Referenced on The WasteWatcher blog
“Matrix Global Advisors pointed out where the focus on fighting opioids needs to be. Approximately 36 percent of people that are misusing painkillers get their drugs from doctors.”
Healthcare Pubs Cite MGA Analysis of Proposed Rule to Restrict Drug Rebates
This week, two healthcare publications referenced MGA’s recent report concerning the HHS OIG proposed rule to restrict drug manufacturer rebates to pharmacy benefit managers (PBMs).
New MGA Analysis Highlights Problems with Proposal to Restrict Drug Manufacturer Rebates
This MGA analysis details concerns with a proposed rule from the Health and Human Services Office of Inspector General that would restrict drug manufacturer rebates to pharmacy benefit managers in Medicare Part D and Medicaid Managed Care Organizations. Not only does the propose rule lack evidence, but it is poorly targeted to achieve its stated goals. I
MGA’s Alex Brill on CNBC’s Squawk Box
The fourth quarter economic reports show less growth than expected. Brill shares his opinion that “things are slowing a little bit around the world and its a little bit of a timing effect between the seasonal issues that we know and the shutdown issues as well.”
Action on Climate Change Should Not Include Creation of New Entitlements
Over the last two years, the United States has scaled back Obama-era climate change policies, withdrawing from the Paris Agreement and rolling back climate-related regulations.
Carbon Tax Most Efficient in Tackling Climate Change
It is encouraging to see more and more fellow Republicans shed the reflexive skepticism about climate change that has characterized the GOP for years. Now, Republicans need to offer solutions.
Navigating the Evolving Opioid Crisis: A Conversation with House Committee on Energy and Commerce Republican Leader Greg Walden (R-OR)
On February 27, a panel of addiction experts and community leaders joined Rep. Greg Walden (R-OR) to discuss the nation’s ongoing efforts to curb opioid misuse and addiction.
Green New Deal Will Stifle Green Energy Innovation, Expert Says
The Washington Free Beacon referenced Alex Brill’s recent op-ed talking about the costs of the proposed Green New Deal.
“AEI resident fellow Alex Brill explained last week that regardless of cost, the unintended consequences of the Green New Deal are “the worst imaginable.”
MGA’a Alex Brill on KSRO
Brill discusses the opioid tax on big pharma in an interview for KSRO stating, “it’s going to result in higher prices for those opioids. But the out-of-pockets costs for the person filling the prescription is likely to remain the same.”
- Biden Budget Proposes a Step Toward Biologic Drug Competition
- MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
- Implications of Cannabis Legalization for the US Federal Budget
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
- The Next Tax Fight: SALT
- Alex Brill on Single-Payer Health Care System and Drug Costs
- New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
- The Threat to Preferred Pharmacy Networks
- Alex Brill mentioned on MSN
- Alex Brill Speaks on Consequences of Proposed PBM Constraints
